<DOC>
	<DOC>NCT01834638</DOC>
	<brief_summary>This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).</brief_summary>
	<brief_title>Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>The subject was randomized into Study M10855 and completed through Week 26 in that study. The subject is receiving one or more antipsychotic medications. Additional history collected during participation in Study M10855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia. The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10855 that indicates the subject is likely to become medically unstable during the current study. The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor. The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>schizophrenia</keyword>
</DOC>